Navigation Links
Pairnomix Presents Systematic Approach To Identifying Approved Drugs That May Be Repurposed For Treatment Of Rare Genetic Diseases
Date:12/4/2016

HOUSTON, Dec. 3, 2016 /PRNewswire/ -- Pairnomix, LLC, a genetic research company and member of the Patient-Empowered Precision Medicine Alliance (PEPMA) recognized by the White House, today announced that findings from its first case study of an individualized approach to the identification of candidate therapies for a patient with epileptic encephalopathy caused by a mutation in the SCN8A gene were presented at the 70th Annual Meeting of the American Epilepsy Society in Houston, TX, December 2-6, 2016. 

Pairnomix' unique process involves creating a model of a patient's genetic mutation, learning about the functional consequences of that mutation, and testing approved drugs against the model to identify potential new treatment options.  Findings are provided to the patient's physician so together they can make better-informed healthcare decisions.

"We are very pleased to share these findings with the epilepsy community, and are gratified to be able to illustrate that it is possible to take a comprehensive approach to exploring opportunities for potentially repurposing approved drugs in the treatment of severe genetic epilepsies," said David Goldstein, PhD, Founding Scientist.

Pairnomix is working on additional cases and is proud of its ongoing collaboration with the KCNQ2 Cure Alliance to bring its highly personalized genetic evaluations to physicians for individuals living with KCNQ2 epileptic encephalopathy.

What is SCN8A?
SCN8A is a gene encoding the alpha-8 subunit of the Nav1.6 sodium channel. For more information, please reach out to the Cute Syndrome Foundation

About the Case Study
The individual was diagnosed with early infantile epileptic encephalopathy combined with global developmental delay and experienced lack of seizure control even after being prescribed many common anti-epileptic drugs (AEDs). The patient's physician ordered next-generation sequencing services, and a de novo mutation in the SCN8A gene was identified.

High throughput screening with more than 1,300 approved drugs identified 90 which significantly inhibited the gain-of-function phenotype conferred by the patient's mutation. These drugs may be potential therapeutic options for physicians to consider when evaluating patients with this specific mutation.  

About Pairnomix
Pairnomix™, a genetic research company, is committed to helping people living with rare diseases understand the genetic cause of their condition. Pairnomix' initial focus is to provide personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit www.pairnomix.com.

Logo - http://photos.prnewswire.com/prnh/20151203/292940LOGO 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pairnomix-presents-systematic-approach-to-identifying-approved-drugs-that-may-be-repurposed-for-treatment-of-rare-genetic-diseases-300372255.html


'/>"/>
SOURCE Pairnomix, LLC
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
2. BioElectronics Presents FDA Reclassification Panel
3. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
4. NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting
5. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. NewLink Genetics Presents Results from Two Phase 1 Studies with Immunotherapy Agent, Indoximod, at the ASCO 2013 Annual Meeting
8. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
9. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the FedEx St. Jude Classic
10. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
11. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
(Date:5/18/2017)... , May 18, 2017  Two Bayer U.S. ... Association (HBA) during its recent 28 th ... City.  The event showcases HBA,s longstanding mission of furthering ... of healthcare. Cindy Powell-Steffen , senior ... U.S. Radiology division, and Libby Howe , a ...
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... ... first ever copper, antimicrobial, mesh back 24/7 task chair specifically designed for clinical ... “We are thrilled to partner with Cupron® to provide customers with a ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on Kickstarter , ... be available at a discounted crowdfunding price on Indiegogo . , “Along with ... also wanted to bring a fidget toy to the market that was made of ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
(Date:5/26/2017)... ... 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in ... post on insurance options. If a Bay Area patient has to search for a ... money. Visiting an in-network provider for a second opinion can ensure a patient receives ...
(Date:5/26/2017)... ... 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the personal journey of Bob ... is the creation of published authors, Bob and Margaret Massey. Bob Massey is small ... "panther quick and leather tough." His love for others is apparent in all of ...
Breaking Medicine News(10 mins):